Alkem Laboratories Dividend 2026 — ₹10 Final Dividend, Record Date 7 Aug, Yield Analysis

At its board meeting held on 28 May 2026, the Board of Directors of Alkem Laboratories Ltd recommended a final dividend of ₹10 per equity share (face value ₹2 each) for the financial year ended 31 March 2026. The recommendation is placed for shareholder approval at the company’s 52nd Annual General Meeting.

The face-value illusion

A “500% dividend” sounds enormous, but that percentage is calculated on the ₹2 face value, not on the market price. On the ₹2 face value, ₹10 is indeed 500%. On a share you buy near ₹5,382, however, the ₹10 final dividend is a cash yield of only about 0.19%. That is the number that actually lands in your bank account relative to what you invested.

The earnings-quality catch aggregators miss

At first glance FY26 looks like a slow-growth year — net profit up just 6.1%. But look closer: revenue grew 13.5% and operating profit grew nearly 20%. The gap between strong operating growth and modest profit growth is explained by two below-the-line factors, not weak operations:

• Other income fell 17.6% (₹494 Cr to ₹407 Cr). FY25 profit was flattered by unusually high non-operating income.
• Tax rate normalised from ~12% in FY25 to ~18% in FY26, taking a bigger bite out of pre-tax profit.
• A one-time loss of about ₹135 crore in the March 2026 quarter (including a ₹60.27 crore gratuity/leave provision) further dampened reported Q4 profit.

In other words, FY26 earnings are arguably higher quality than the 6% headline suggests, because more of the profit came from the core operating business and less from one-off gains.

Reported profit is an accounting opinion; cash is fact. On this test Alkem looks solid. In FY26 the company generated ₹1,963 crore of operating cash flow and ₹1,476 crore of free cash flow — comfortably more than its entire FY26 dividend outflow of about ₹633.72 crore (interim plus final).

Overall: Sustainable

On all four tests — earnings, operating cash, free cash and balance-sheet liquidity — the FY26 dividend clears the bar comfortably. The payout ratio of about 27% leaves ample profit for reinvestment, and cash generation more than doubly covers the cash paid out. The classification is Sustainable. The main forward caveat is the guided step-up in the tax rate for FY27 (see Key Risks), which could compress reported earnings even if operations stay healthy.

Where Alkem sits

Indian pharma is structurally a low-yield sector — dividend yields across the majors cluster below 1%, because these are growth businesses trading at high multiples. On that yardstick, Alkem’s ~0.98% full-year yield is at the upper end of the peer pack, and its return ratios (ROE ~19%, ROCE ~21%) are competitive with much larger rivals. Investors chasing high dividend yield will not find it here or among peers; the appeal is steady, growing, well-covered payouts alongside capital growth.

How dividends are taxed in India

Since April 2020, dividends are taxed in the hands of the shareholder at their applicable income-tax slab rate; there is no separate dividend distribution tax at the company level. The company deducts TDS at 10% under Section 194 if the total dividend paid to a resident shareholder exceeds ₹10,000 in a financial year (the threshold was raised from ₹5,000). TDS is not a final tax — it is adjusted against your overall liability when you file your return.

Worked example — 1,000 shares, final dividend ₹10, 30% slab

For a shareholder who received the full FY26 dividend of ₹53 per share (₹53,000 on 1,000 shares), tax at a 30% slab plus cess would be about ₹16,536, leaving roughly ₹36,464 in hand — a post-tax yield of about 0.68% on the CMP. Actual tax depends on your slab; consult a tax adviser.

• Tax rate step-up in FY27: Management and brokerages flag a rise in the effective tax rate from ~18% (FY26) to ~27-29% (FY27) as the company moves to the new tax regime. This alone can compress reported EPS even if the business grows, and could pressure the payout ratio.
• US FDA / regulatory risk: The Amaliya (Daman) facility received a Form 483 with 7 observations and an “Official Action Indicated” (OAI) classification. Adverse US regulatory outcomes can disrupt US revenue and approvals.
• Leadership transition: The CEO, Dr. Vikas Gupta, resigned effective 30 June 2026. Senior-management change introduces execution and continuity risk during a period of strategic diversification.
• Acquisition and diversification execution: The move into medtech via the Occlutech (Switzerland) acquisition takes Alkem outside its core pharma competency; integration and margin ramp-up carry execution risk, and borrowings have risen.
• Restructuring and comparability: The transfer of the Generic Business Undertaking to Alkem Wellness Limited (01 Oct 2025) reshapes the reported entity, complicating year-on-year comparisons and introducing corporate-action complexity.
• Modest medium-term growth and lumpy profits: Five-year sales growth has been a subdued ~10.7%, quarterly margins are seasonal, and one-off items (like the ~₹135 Cr Q4 FY26 loss) can swing reported profit.

• Effective tax rate in FY27 results: Watch whether the guided move to ~27-29% materialises and how it flows through to EPS and the dividend.
• Promoter holding trajectory: Track whether the slide below 50% (now 49.70%) continues or stabilises in subsequent shareholding disclosures.
• US FDA resolution: Follow updates on the Amaliya OAI status and any re-inspection outcomes, which gate US business momentum.
• Operating margin and working capital: Monitor whether EBITDA margins hold near 20% and whether debtor/inventory days stabilise so operating cash keeps covering the dividend.
• New-product and diversification ramp: Watch traction in biosimilars, the semaglutide launch, the Occlutech medtech business and the CDMO vertical for the next leg of growth.
• Dividend policy consistency: Check whether the company sustains its ~25-28% payout discipline once the FY27 tax drag is absorbed.

Alkem Laboratories’ ₹10 final dividend for FY26 is a small cash return in percentage terms — about 0.19% on the current price — and it is the junior partner to the much larger ₹43 interim dividend that took the full-year payout to ₹53 (a ~0.98% yield). The “500%” headline reflects face value, not the return on your investment.

On the metrics that matter, the dividend is well-supported: it is covered ~3.6x by earnings, ~3.1x by operating cash flow and ~2.3x by free cash flow, and it sits on a near-net-cash balance sheet with ~21% ROCE. The dividend is Sustainable. The genuinely interesting signals are elsewhere — the higher-quality (if optically slower) FY26 profit, the promoter stake slipping below 50%, and a looming tax-rate step-up in FY27 that investors should factor into forward expectations.